生长分化因子15与糖尿病相关性实验研究进展  

Progress of Experimental Research on the Correlation Between Growth Differentiation Factor 15 and Diabetes Mellitus

作　　者：肖俊 程琪 周鸿禹 汪文 王兴亚[1] XIAO Jun;CHENG Qi;ZHOU Hongyu;WANG Wen;WANG Xingya(School of Pharmaceutical Sciences,Zhejiang Chinese Medical University,Hangzhou 311400,China)

机构地区：[1]浙江中医药大学药学院,杭州311400

出　　处：《中国现代应用药学》2025年第2期301-311,共11页Chinese Journal of Modern Applied Pharmacy

基　　金：国家自然科学基金项目(81973521)。

摘　　要：糖尿病及其并发症是日益严重的代谢流行疾病,是世界范围内一个重要的健康和社会经济问题。因此,为了减少糖尿病和相关并发症的发生发展,尚需寻找新的潜在药物靶点。非甾体抗炎药激活因子基因-1(non-steroidal anti-inflammatory drug activated gene-1,NAG-1)又称生长分化因子15(growth differentiation factor 15,GDF15),是转化生长因子-β(transforming growth factor-β,TGF-β)超家族的一个分化成员(以下简称NAG-1/GDF15)。NAG-1/GDF15在多种疾病中发挥重要调节作用,包括癌症、心血管疾病、肥胖和糖尿病等。本文先简要介绍了NAG-1/GDF15的结构、表达及调控机制,重点介绍了NAG-1/GDF15在糖尿病相关体内和体外研究中的进展和分子机制,并对通过调控NAG-1/GDF15发挥抗糖尿病作用的药物进行总结。从多方面为NAG-1/GDF15在糖尿病及相关代谢疾病中的基础研究和调控NAG-1/GDF15抗糖尿病药物开发提供理论依据。Diabetes mellitus and its complications are serious epidemic diseases associated with metabolism and an important health and socioeconomic problem worldwide.Therefore,there is still a need to find new drug targets to reduce the occurrence and development of diabetes mellitus and related complications.Non-steroidal anti-inflammatory drug activator gene-1(NAG-1),also known as growth differentiation factor 15(GDF15),is a divergent member of the transforming growth factor-β(TGF-β)superfamily(hereinafter referred to as NAG-1/GDF15).NAG-1/GDF15 plays an important regulatory role in a variety of diseases,including cancer,cardiovascular diseases,obesity,and diabetes mellitus.This review briefly introduced the structure and expression regulation mechanism of NAG-1/GDF15,focused on the research progress and molecular mechanism of NAG-1/GDF15 in diabetes mellitus-related in vivo and in vitro studies,and summarized the research of anti-diabetic drug regulating NAG-1/GDF15.This review will provided a theoretical basis for the basic research of NAG-1/GDF15 in diabetes mellitus and related metabolic diseases and the development of anti-diabetic drugs regulating NAG-1/GDF15 from a broad aspect.

关 键 词：NAG-1/GDF15 糖尿病 肥胖 二甲双胍 

分 类 号：R363[医药卫生—病理学]